On April 13, 2018 Syndax Pharmaceuticals, Inc. ("Syndax,"the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported twelve oral and poster presentations at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held April 14-18, 2018 in Chicago, Illinois (Press release, Syndax, APR 13, 2018, View Source [SID1234525305]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on Presentations
Oral Presentations:
Title: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors – results from SNDX-275- 0141 phase I trial
Presenter: Anthony W. Tolcher, M.D.
Category: Clinical Trials
Session: Biomarkers in Immuno-oncology
Abstract Number: CT179
Location: N Hall C – McCormick Place North (Level 1)
Date and Time: Tuesday April 17, 2018; 3:50 PM – 4:05 PM C.T.
Title: VTP-50469 is a novel, orally-available Menin-MLL1 targeted inhibitor effective against MLL-Rearranged and NPM1-mutant leukemia
Presenter: Andrei V. Krivtsov, PhD
Category: Experimental and Molecular Therapeutics
Session: Early Novel Drug Development
Abstract Number: 4958
Location: McCormick Place South, Room S102 (Level 1)
Date and Time: Tuesday April 17, 2018; 3:50 PM – 4:05 PM C.T.
Title: Entinostat transforms the suppressive tumor microenvironment of breast

Title: Epigenetic reprogramming of the tumor microenvironment by Entinostat increases tumor sensitivity to multivalent immunotherapy combinations with an IL-15 superagonist plus vaccine or immune checkpoint blockade
Category: Immunology
Session: Modifiers of the Tumor Microenvironment 2
Abstract Number: 1740
Location: McCormick Place South, Exhibit Hall A, Poster Section 33
Date and Time: Monday April 16, 2018; 8:00 AM – 12:00 PM C.T.
Title: Epigenetic modulation of the tumor microenvironment enhances immune checkpoint
efficacy in a murine model of pancreatic cancer
Category: Immunology
Session: Modifiers of the Tumor Microenvironment 2
Abstract Number: 1746
Location: McCormick Place South, Exhibit Hall A, Poster Section 33
Date and Time: Monday April 16, 2018; 8:00 AM – 12:00 PM C.T.
Title: Activity of entinostat alone and in combination with cisplatin in a panel of low passage adenoid cystic carcinoma patient-derived xenograft (PDX) models
Category: Tumor Biology
Session: Translational Therapeutics in Cancer Models 2
Abstract Number: 2146
Location: McCormick Place South, Exhibit Hall A, Poster Section 7
Date and Time: Monday April 16, 2018; 1:00 PM – 5:00 PM C.T.
Title: Antitumor activity of HDAC inhibition in bladder cancer mouse models correlates with enhanced immune response
Category: Immunology
Session: Immune Mechanisms Invoked by Therapies 1
Abstract Number: 2748
Location: McCormick Place South, Exhibit Hall A, Poster Section 33
Date and Time: Monday April 16, 2018; 1:00 PM – 5:00 PM C.T.
Title: Overcoming resistance to DNA targeted agents by epigenetic activation of Schlafen 11
(SLFN11) expression with class I histone deacetylase inhibitors
Category: Molecular and Cellular Biology/Genetics
Session: Late-Breaking Research: Molecular and Cellular Biology / Genetics 2
Abstract Number: LB-244
Location: McCormick Place South, Exhibit Hall A, Poster Section 45
Date and Time: Tuesday April 17, 2018; 8:00 AM – 12:00 PM C.T.
Title: Pediatric Preclinical Testing Consortium evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia
Category: Tumor Biology
Session: Pediatrics 2: Preclinical Therapies, Resistance, and Stem Cells
Abstract Number: 3187
Location: McCormick Place South, Exhibit Hall A, Poster Section 7
Date and Time: Tuesday April 17, 2018; 8:00 AM – 12:00 PM C.T.

Title: Histone deacetylase inhibitor, Entinostat enhances the tumor specific immune response by generating T-cell central memory in the TME
Category: Immunology
Session: Immunomodulatory Agents and Interventions 1
Abstract Number: 3761
Location: McCormick Place South, Exhibit Hall A, Poster Section 32
Date and Time: Tuesday April 17, 2018; 8:00 AM – 12:00 PM C.T.
Title: Manipulating the breast tumor microenvironment with histone deacetylase inhibitors for
more robust and durable T cell responses
Category: Immunology
Session: Immunomodulatory Agents and Interventions 2
Abstract Number: 4700
Location: McCormick Place South, Exhibit Hall A, Poster Section 33
Date and Time: Tuesday April 17, 2018; 1:00 PM – 5:00 PM C.T.
All accepted abstracts will be published in the 2018 Proceedings of the AACR (Free AACR Whitepaper). Session
information is available online via the Annual Meeting Itinerary Planner through the AACR (Free AACR Whitepaper) website
at www.aacr.org.